Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming
Faye A H Cooles,Jessica Tarn,Dennis W Lendrem,Najib Naamane,Chung Ma Lin,Ben Millar,Nicola J Maney,Amy E Anderson,Nishanthi Thalayasingam,Julie Diboll,Vincent Bondet,Darragh Duffy,Michael R Barnes,Graham R Smith,Sandra Ng,David Watson,Rafael Henkin,Andrew P Cope,Louise N Reynard,Arthur G Pratt,RA-MAP Consortium,John D Isaacs,Adwoa Hughes-Morley,Alexandra Walker,Alexandru Cuza,Amaya Gallagher-Syed,Amy Anderson,Andrea Haynes,Andrew Filer,Andrew Long,Angela Parke,Anthony Rowe,Arnaud Didierlaurent,Ashley Gilmour,Athula Herath,Ayako Wakatsuki,Pedersen Aysin,Tulunay Virlan,Ben Allen,Benjamin A Fisher,Blerina Kola,Bohdan Harvey,Brian Tom,Carl S Goodyear,Carolyn Cuff,Catharien Hilkens,Catharina Lindholm,Catherine T Mela,Christopher D Buckley,Chris Larminie,Chris Marshall,Christopher John,Christopher M Mela,Claudio Carini,Costantino Pitzalis,Coziana Ciurtin,Dan Baker,Daniel Ziemek,Daniela Dastros-Pitei,Dao Nguyen,David L Scott,David S Watson,Deborah Symmons,Dennis Lendrem,Denny Verbeeck,Desmond Padhji,Donna Finch,Duncan Porter,Emma Vernon,Faye Cooles,Feng Hong,Fiona Clarke,Fiona Stirling,Fowzia Ibrahim,Frances Humby,Francisco Bonachela Capdevila,Frederic Geissmann,Frederique Ponchel,Gemma Molyneux,Gemma Simpson,Georgina Thorborn,Gerry Parker,Gioia Altobelli,Hannah Edwards,Hannah Tipney,Hans-Dieter Zucht,Hayley Noble,Heidi Lempp,Humayara AliIain B McInnes,Ian C Scott,Ian N BruceIona Donnelly,Ivana Vranic,James A Butler,James Galloway,Jamie C Sergeant,Jane Worthington,Jehan El-Jawhari,Joanne Ellis,John Casement,John Isaacs,Karim Raza,Katriona Goldmann,Kirsty Hicks,Liliane Fossati-Jimack,Lucy Rowell,Marc Levesque,Mark C Coles,Mark Coles,Mark Curran,Martin Hodge,Martin Jenkins,Mateusz Maciejewski,Matt Page,Matthew A Sleeman,Matthew J Loza,Maya Buch,Meilien Ho,Michael Binks,Michael F McDermott,Michael Macoritto,Michael R Ehrenstein,Michele Bombardieri,Myles Lewis,Neil Gozzard,Neil Payne,Neil Ward,Nina Joseph,Paul Emery,Peter C Taylor,Peter Schulz-Knappe,Petra Budde,Philip Jones,Philip Stocks,Rachel Harry,Ravi Rao,Ray Harris,Rekha Parmar,Ruth Toward,Sally Hollis,Samana Schwank,Samantha Lipsky,Samiul Hasan,Sandra Martins,Sarah Brockbank,Sarah Keidel,Scott Jelinsky,Sharmila Rana,Simon Read,Stephen Kelly,Stephen Wright,Steve P Young,Sukru Kaymakcalan,Susan Talbot,Suzanne Mm Verstappen,Tomi Lazarov,Tony Sabin,Valerie Ludbrook,Vernon Farewell,Wayne Tsuji,Wing Wu,Wivine Burny,Yujie Zhong,Zheng Liu,Zhilong Jia
DOI: https://doi.org/10.1136/annrheumdis-2022-222370
2022-08-11
Abstract:Objectives: An interferon (IFN) gene signature (IGS) is present in approximately 50% of early, treatment naive rheumatoid arthritis (eRA) patients where it has been shown to negatively impact initial response to treatment. We wished to validate this effect and explore potential mechanisms of action. Methods: In a multicentre inception cohort of eRA patients (n=191), we examined the whole blood IGS (MxA, IFI44L, OAS1, IFI6, ISG15) with reference to circulating IFN proteins, clinical outcomes and epigenetic influences on circulating CD19+ B and CD4+ T lymphocytes. Results: We reproduced our previous findings demonstrating a raised baseline IGS. We additionally showed, for the first time, that the IGS in eRA reflects circulating IFN-α protein. Paired longitudinal analysis demonstrated a significant reduction between baseline and 6-month IGS and IFN-α levels (p<0.0001 for both). Despite this fall, a raised baseline IGS predicted worse 6-month clinical outcomes such as increased disease activity score (DAS-28, p=0.025) and lower likelihood of a good EULAR clinical response (p=0.034), which was independent of other conventional predictors of disease activity and clinical response. Molecular analysis of CD4+ T cells and CD19+ B cells demonstrated differentially methylated CPG sites and dysregulated expression of disease relevant genes, including PARP9, STAT1, and EPSTI1, associated with baseline IGS/IFNα levels. Differentially methylated CPG sites implicated altered transcription factor binding in B cells (GATA3, ETSI, NFATC2, EZH2) and T cells (p300, HIF1α). Conclusions: Our data suggest that, in eRA, IFN-α can cause a sustained, epigenetically mediated, pathogenic increase in lymphocyte activation and proliferation, and that the IGS is, therefore, a robust prognostic biomarker. Its persistent harmful effects provide a rationale for the initial therapeutic targeting of IFN-α in selected patients with eRA.